Aveva 250 mg PFS Combipack Injection contains Fulvestrant, used to treat breast cancer in postmenopausal women. Additionally, Aveva 250 mg PFS Combipack Injection may be used in combination with palbociclib to treat women with a type of breast cancer called hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that is locally advanced or has spread to other parts of the body (metastatic).

FAQs

How does Aveva 250 mg PFS Combipack Injection work?

Aveva 250 mg PFS Combipack Injection contains Fulvestrant which works by inhibiting some of the actions of estrogen (female sex hormone) and reducing the amount that is in the body. Thus, it helps in reducing breast cancer tumour growth.

Is Aveva 250 mg PFS Combipack Injection safe for patients with liver problems?

Aveva 250 mg PFS Combipack Injection is not recommended for patients with severe liver problems. Therefore, if you have any liver problems, inform your doctor before receiving Aveva 250 mg PFS Combipack Injection .

Does Aveva 250 mg PFS Combipack Injection cause weakness?

Aveva 250 mg PFS Combipack Injection may cause weakness or tiredness as a common side effect. However, if weakness persists or worsens, please consult your doctor.